Applied Therapeutics Inc
APLT0.460USD
+0.020+4.47%
交易中 （美東）報價延遲15分鐘
65.18M總市值
虧損本益比TTM
關於 Applied Therapeutics Inc 公司
Applied Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發一系列針對已驗證的分子靶點的新型候選藥物，以治療高度未滿足的醫療需求。該公司的主要候選藥物 govorestat 是一種新型中樞神經系統滲透性醛糖還原酶抑制劑 (ARI)，用於治療中樞神經系統 (CNS) 罕見代謝疾病，包括半乳糖血症、山梨醇脫氫酶 (SORD) 缺乏症和 PMM2-CDG。該公司還在開發一種新型強效 ARI AT-001，用於治療糖尿病性心肌病 (DbCM)，這是一種致命的心臟纖維化。該公司已完成 I/II 期臨牀試驗，評估 AT-001 對約 120 名 2 型糖尿病患者的療效，未觀察到與藥物相關的不良反應或耐受性問題。臨牀前管線還包括 AT-003，這是一種口服時可穿過眼球后部的 ARI，用於治療糖尿病視網膜病變。
公司簡介
公司代碼APLT
公司名稱Applied Therapeutics Inc
上市日期May 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
員工數量35
證券類型Ordinary Share
年結日May 09
公司地址545 Fifth Avenue, Suite 1400
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編10017
電話12122209226
網址https://www.appliedtherapeutics.com/
公司代碼APLT
上市日期May 09, 2019
CEOMr. Leslie D. (Les) Funtleyder
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Teena L. Lerner, Ph.D.
Dr. Teena L. Lerner, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Dale Hooks
Mr. Dale Hooks
Chief Commercial Officer
Chief Commercial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Evan Prescott Bailey ,
Evan Prescott Bailey ,
Chief Medical Officer
Chief Medical Officer
841.67K
--
Mr. Leslie D. (Les) Funtleyder
Mr. Leslie D. (Les) Funtleyder
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
560.81K
+36.51%
Ms. Stacy J. Kanter, J.D.
Ms. Stacy J. Kanter, J.D.
Independent Director
Independent Director
119.25K
+10.42%
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Chief Operating Officer and Chief Business Officer
Chief Operating Officer and Chief Business Officer
90.19K
-71.94%
Dr. Jay S. Skyler, M.D.
Dr. Jay S. Skyler, M.D.
Independent Director
Independent Director
65.00K
--
Ms. Catherine Thorpe
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Interim Chief Accounting Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月20日 週二
更新時間: 5月20日 週二
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
11.03%
Vestal Point Capital, LP
8.12%
Propel Bio Management, LLC
7.97%
BlackRock Institutional Trust Company, N.A.
6.33%
Knoll Capital Management, LLC
5.51%
Other
61.04%
股東類型
持股股東
佔比
Investment Advisor
33.47%
Hedge Fund
18.25%
Investment Advisor/Hedge Fund
15.40%
Venture Capital
11.90%
Individual Investor
5.70%
Research Firm
2.36%
Private Equity
0.61%
Sovereign Wealth Fund
0.17%
Bank and Trust
0.07%
Other
12.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
297
124.40M
87.87%
-35.48M
2025Q1
297
123.70M
87.51%
-30.40M
2024Q4
287
131.75M
113.23%
-13.70M
2024Q3
251
128.75M
112.47%
+2.21M
2024Q2
218
117.82M
104.34%
+1.65M
2024Q1
214
107.47M
96.19%
+20.49M
2023Q4
204
75.60M
89.15%
+10.52M
2023Q3
201
57.91M
82.88%
+2.25M
2023Q2
197
52.05M
93.62%
+2.03M
2023Q1
199
42.23M
88.25%
+6.29M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
15.61M
11.03%
+5.23M
+50.40%
Apr 30, 2025
Vestal Point Capital, LP
11.50M
8.12%
--
--
Mar 31, 2025
Propel Bio Management, LLC
11.29M
7.97%
+1.67M
+17.37%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.96M
6.33%
+266.41K
+3.07%
Mar 31, 2025
Knoll Capital Management, LLC
7.80M
5.51%
+2.00M
+34.48%
Mar 31, 2025
VR Adviser, LLC
5.57M
3.93%
-4.42M
-44.27%
Mar 31, 2025
Alexandria Real Estate Equities, Inc.
5.39M
3.81%
-300.00K
-5.27%
Nov 13, 2024
The Vanguard Group, Inc.
5.89M
4.16%
+358.20K
+6.48%
Mar 31, 2025
Shendelman (Shoshana)
4.72M
3.34%
-567.10K
-10.72%
Aug 14, 2024
Schonfeld Strategic Advisors LLC
4.67M
3.3%
-4.09M
-46.66%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Simplify Propel Opportunities ETF
2.06%
Hypatia Women CEO ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
SPDR S&P Biotech ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Humankind US Stock ETF
0%
查看更多
Simplify Propel Opportunities ETF
佔比2.06%
Hypatia Women CEO ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Biotechnology ETF
佔比0%
SPDR S&P Biotech ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
Humankind US Stock ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
